Loading…
Employees: 754
Size Hunan Sundy Science and Technology (300515.SZ) is a China Health Care company (Medical Specialties) with a market value of $453M, the 4089th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.93 on 6 Nov 2026.
Performance Over six months the shares fell 12.8%, against -14.7% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 10.0% over the last twelve months (peer median -0.6%); the operating margin is 26.6% (peer median 3.7%).
Valuation It trades at 14.1× forward earnings against a peer median of 23.6× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 14.4 points above its cost of capital (7.0% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥733M | CN¥653M | CN¥572M | CN¥460M | CN¥390M |
| Revenue growth | — | +14% | +24% | +18% | — |
| Gross profit | CN¥401M | CN¥339M | CN¥293M | CN¥257M | CN¥220M |
| EBITDA | n/a | CN¥209M | CN¥166M | CN¥50.8M | CN¥106M |
| Net income | CN¥221M | CN¥184M | CN¥143M | CN¥53.7M | CN¥92.2M |
| Free cash flow | CN¥211M | CN¥213M | CN¥172M | CN¥121M | CN¥111M |
| Capital expenditure | CN¥5.80M | CN¥4.68M | CN¥9.89M | CN¥30.0M | CN¥40.0M |
| Total debt | CN¥33.2M | CN¥46.0M | CN¥22.7M | CN¥34.1M | CN¥26.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300515.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -7.2% | 10th highest of 21 |
| 6-month return | -12.8% | -14.7% | 10th highest of 21 |
| Distance from 52-week high | -37.6% | -37.1% | 11th highest of 21 |
| Revenue growth (TTM) | +10.0% | -0.6% | 5th highest of 21 |
| Operating margin | 26.6% | 3.7% | highest of 21 |
| Forward P/E | 14.1× | 23.6× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 0.9% | 17.0% | least demanding of 11 |
| Growth delivered (Del g) | +15.6% | +1.3% | 2nd highest of 11 |
| Hurdle (Req g minus delivered) | -14.7 pp | +11.0 pp | least demanding of 11 |
| ROIC minus cost of capital | +14.4 pp | -4.5 pp | highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 27.4× | 34.3% | +18.8% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 21.6× | 11.8% | +5.6% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | n/a | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | n/a | n/a | n/a |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 9.0× | n/a | n/a |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | n/a | n/a | n/a |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | n/a | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |